Kidney international

Kidney international
Audio Summaries

Every issue of Kidney international moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.

157 audio summariesNLM Catalog

Specialties

Kidney international covers research in these specialties.

Recent summaries

The latest articles summarized from Kidney international.

Proliferative Glomerulonephritis with "Monoclonal" Immunoglobulin Deposits: Time for Revising the Name and a New Classification.

Nov 20, 2026

This paper proposes renaming proliferative glomerulonephritis with "monoclonal" immunoglobulin deposits (PGNMID) to "proliferative glomerulonephritis with monotypic immunoglobulin deposits," since recent evidence challenges its link to monoclonal gammopathy, especially for IgG3 cases where clonal detection is rare and deposits are often polyclonal. The authors also propose dividing the disease into MGRS-associated and non-MGRS subtypes, with biopsy reports specifying immunoglobulin class and subclass to guide hematologic evaluation and precision therapy.

The effects of size and sex mismatch on kidney functional adaption following living donor kidney transplantation.

Nov 20, 2026

This longitudinal cohort study of 194 living-donor kidney transplants asked how donor-recipient body size and sex mismatches affect functional adaptation of the transplanted kidney, and whether this adaptation involves harmful hyperfiltration injury. Using isotopic mGFR measured from each donor kidney at implantation and at 12 months, the authors found that adaptation was greatest when smaller female donor kidneys went into larger male recipients, and that it correlated with body surface area and BMI mismatch and with recipient lean body mass. At 12 months there was no histological, podocyte, or albuminuria evidence of maladaptive hyperfiltration injury, suggesting the adaptation is a benign response scaled to recipient metabolic need.

Uremic toxin clearance in pediatric hemodialysis: fishing upstream may improve the catch.

Nov 19, 2026

This commentary discusses whether small-solute clearance measured by blood urea nitrogen adequately reflects the removal of larger, more harmful uremic toxins in pediatric hemodialysis patients. It highlights that convective therapies, particularly pre-dilution hemofiltration, can enhance clearance of these larger molecules, with post-dilution being more efficient but limited by dialyzer hemoconcentration. The commentary focuses on a prospective pediatric crossover trial by Agbas et al., which suggests that pre-hemofiltration improves clearance of many uremic toxins.

Scaling human organoid models for drug discovery in polycystic kidney disease.

Nov 19, 2026

This commentary-style piece asks whether human kidney organoids can serve as a scalable, reproducible platform for drug discovery in polycystic kidney disease, given the variability and limited throughput of existing models. The authors (Vanichapol et al., as described by Combes) show that suspension culture of ureteric epithelium-like organoids with PKD2 loss produces rapid, highly penetrant cysts suitable for screening. The work also identifies Toll-like receptor 4 signaling as a candidate regulator of cyst growth and shows that epithelial identity and maturation state influence drug responses.

What's the T? Endogenous testosterone and healthy age-related glomerular filtration rate decline in cisgender men.

Nov 19, 2026

This study asks whether endogenous testosterone drives age-related glomerular filtration rate (GFR) decline in healthy middle-aged cisgender men, given known sex differences in kidney function. Using longitudinal iohexol plasma clearance measurements from the Renal Iohexol Clearance Survey, the authors found that testosterone was associated with baseline measured GFR but not with its subsequent decline in multivariable models. They conclude that endogenous testosterone does not appear to be a driver of age-related GFR decline in this population.

Secondary analysis of the FIELD randomized trial evaluated the performance of GFR slope in a non-glomerular model of estimated GFR decline.

Nov 19, 2026

This secondary analysis of the FIELD trial asked whether GFR slope measures can reliably predict clinical kidney outcomes when a drug causes an acute, non-glomerular eGFR dip, using fenofibrate as the test case. Fenofibrate produced an early eGFR decline of about 9 mL/min/1.73 m² and improved chronic slope but worsened total slope, while significantly increasing the clinical composite kidney endpoint (HR 1.48). The authors conclude that total slope and the conventional composite gave concordant treatment effects, though the abstract's mixed slope results and its harm signal make that concordance claim worth examining closely.

Dietary sodium restriction enhances the renoprotective efficacy of endothelin-A receptor antagonism in proteinuric chronic kidney disease.

Nov 19, 2026

Endothelin-A receptor antagonists are emerging treatments for proteinuric chronic kidney disease, but whether dietary sodium intake alters their kidney effects was unknown. In a randomized, double-blind, placebo-controlled crossover study of 12 adults with non-diabetic proteinuric CKD, the authors found that the selective ETA antagonist BQ123 lowered blood pressure and arterial stiffness and increased kidney blood flow regardless of sodium intake, but reduced glomerular filtration rate, filtration fraction, and proteinuria only during 14 days of dietary sodium restriction (6.3 g salt/day) rather than habitual intake (13.3 g/day). These acute findings suggest that sodium restriction may enhance the kidney-protective efficacy of ERAs, though long-term benefit remains to be tested prospectively.

Characterization of the Urine Proteome Using the Olink Explore 3072 Platform.

Nov 18, 2026

This study characterizes the urine proteome using the high-throughput Olink Explore 3072 platform, quantifying 2,868 proteins in 1,268 participants of the German Chronic Kidney Disease (GCKD) cohort. The authors aimed to determine which proteins are reliably detectable in urine and how their levels relate to clinical factors, finding that about 23% of proteins were highly detectable and that albuminuria, sex, and specific CKD etiologies were associated with distinct protein sets. Highly detectable proteins were enriched for extracellular, exosomal, and kidney-related origins, providing a resource for future urinary biomarker discovery.

Peroxisome depletion suppresses clear cell renal cell carcinoma.

Nov 18, 2026

Using peroxisome depletion in clear cell renal cell carcinoma (ccRCC) models, this study asks whether reducing peroxisome abundance affects tumor progression, given that peroxisomes are often lower in low-grade tumors. The authors found that peroxisome loss slowed tumor growth by reducing proliferation, impairing mitochondrial function and metabolic flexibility, and reshaping the tumor microenvironment with increased collagen deposition and a shift toward SERPINH1-positive fibroblasts. These results suggest that peroxisomes contribute to ccRCC metabolic fitness and stromal organization, pointing to peroxisome homeostasis as a potential therapeutic target.

Transfer RNA-derived small RNA-1:34-Asp-GTC-2 promotes sepsis-associated acute kidney injury by regulating kinase SNRK/transcription factor NF-κB signaling.

Nov 18, 2026

This study asks whether tRNA-derived small RNAs contribute to sepsis-associated acute kidney injury (SA-AKI), and identifies tiRNA-1:34-Asp-GTC-2 (tiRNA-Asp) as the most strongly upregulated candidate in LPS-treated mouse kidneys, mainly in tubular epithelial cells. Silencing tiRNA-Asp with an antagomir alleviated inflammation, kidney injury, and NF-κB activation in LPS and ischemia models, while overexpression or knockdown in tubular cells increased or decreased NF-κB signaling and cytokine production. The authors show that tiRNA-Asp drives inflammation by directly suppressing SNRK, an anti-inflammatory kinase, suggesting the tiRNA-Asp/SNRK/NF-κB axis as a possible therapeutic target in SA-AKI.

Listen to Kidney international

14-day free trial. Every new article, summarized in ~3 minutes.